Assuming successful trial results, Maxim Group's OCT 2019 report estimated revenues for IMP321 (Breast Cancer) from milestones and royalties to start in 2022? Although I am not inclined to focus too much on these reports, to what extent do the upcoming results influence these dates (e.g good results - fast track, ok results - another trial?)
- Forums
- ASX - By Stock
- What could go wrong?
IMM
immutep limited
Add to My Watchlist
2.00%
!
24.5¢

Assuming successful trial results, Maxim Group's OCT 2019...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
24.5¢ |
Change
-0.005(2.00%) |
Mkt cap ! $357.7M |
Open | High | Low | Value | Volume |
25.0¢ | 25.0¢ | 24.0¢ | $411.9K | 1.707M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
62 | 450163 | 24.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
24.5¢ | 65313 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
62 | 449785 | 0.240 |
16 | 390443 | 0.235 |
14 | 365103 | 0.230 |
15 | 534329 | 0.225 |
19 | 1300604 | 0.220 |
Price($) | Vol. | No. |
---|---|---|
0.245 | 66330 | 10 |
0.250 | 228591 | 14 |
0.255 | 140238 | 8 |
0.260 | 289028 | 10 |
0.265 | 506313 | 5 |
Last trade - 15.27pm 04/07/2025 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online